INTESTINAL PERMEABILITY & INFLAMMATION - 30ml

ADVANCED DELIVERY SYSTEM - CELL PENETRATING PEPTIDE TECHNOLOGY

This product utilizes advanced delivery technology incorporating calibrated cell-penetrating peptide (CPP) systems. The formulation is engineered to support efficient and targeted intracellular delivery of active ingredients, contributing to enhanced transport performance and bioavailability under controlled laboratory conditions.

SPECIFICATIONS

Product Code: IIPC30L

BPC-157 ARGINATE FORM – 60 mg

Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val × 2 × L-Arg

Molecular Formula: C62H98N16O22

Molecular Weight (peptide): 1418.70 g/mol

CAS: 137525-51-0

Purity: Technical / Research Grade ≥98%

LARAZOTIDE ACETATE – 60 mg

Sequence: GGVLVQPG

Molecular Formula: C32H55N9O10

Molecular Weight: 725.845 g/mol

CAS: 158818-34-7

Purity: Technical / Research Grade ≥98%

KPV – 100 mg

Sequence: Lys-Pro-Val

Molecular Formula: C16H30N4O4

Molecular Weight: 342.43 g/mol

CAS: 67727-97-3

Purity: Technical / Research Grade ≥98%

General Properties

Other details: No TFA Salt

Form: Liquid Solution

Color: Clear / Slightly opalescent

Total Content: 220 mg in 30 mL (7.33 mg/mL total peptide concentration)

Concentration per mL:  BPC-157 Arginate: 2 mg; Larazotide Acetate: 2 mg; KPV: 3.33 mg

Vehicle / Carrier System: Proprietary carrier system

Storage Temperature: 4°C (Do not freeze)

Source: Synthetic

Safety classification: Standard laboratory handling

DESCRIPTION

Intestinal Permeability & Inflammation is a structured multi-peptide formulation developed to support research into the coordinated biological mechanisms that regulate intestinal barrier integrity, epithelial permeability control, and inflammatory balance within the gastrointestinal microenvironment. When the intestinal barrier is exposed to inflammatory stimuli, oxidative stress, microbial imbalance, or immune dysregulation, disruption does not occur through a single mechanism. A defined sequence of biological events typically unfolds:

• Activation of inflammatory mediators
• Disruption of tight junction architecture
• Increased paracellular permeability
• Altered epithelial restitution dynamics
• Microvascular instability within mucosal tissue
• Oxidative stress amplification
• Dysregulated epithelial–immune cross-talk

Barrier dysfunction is not simply “inflammation.” It is the result of structural disorganization combined with immune signaling imbalance and permeability deregulation. The quality of intestinal recovery depends not only on reducing inflammatory signals, but on restoring structural coherence at the epithelial level while maintaining controlled immune activity. This formulation combines peptides that influence complementary domains of intestinal barrier regulation rather than targeting a single isolated pathway. The integrated structure focuses on:

• Stabilization of tight junction complexes
• Modulation of zonulin-associated permeability signaling
• Regulation of inflammatory mediator expression
• Restoration of epithelial restitution dynamics
• Support of mucosal microcirculation
• Reduction of oxidative stress burden
• Reinforcement of epithelial structural continuity

Tight Junction Stabilization and Barrier Integrity

The intestinal epithelium functions as a selective barrier that allows nutrient absorption while preventing uncontrolled passage of luminal antigens and inflammatory triggers. Tight junction proteins — including occludin, claudins, and zonula occludens (ZO-1) — form the structural seal between epithelial cells. When inflammatory cytokines increase or zonulin signaling becomes amplified, these junctional complexes may disassemble, increasing paracellular permeability. Stabilizing tight junction architecture is central to restoring barrier integrity. This complex incorporates components investigated for their interaction with tight junction regulatory systems and zonulin-associated signaling cascades. Preserving junctional organization supports:

• Controlled permeability
• Reduced antigen translocation
• Maintenance of epithelial polarity
• Improved structural continuity

Barrier stability is foundational to intestinal homeostasis.

Regulation of Inflammatory Signaling

Intestinal inflammation involves activation of transcription factors such as NF-κB and downstream cytokines including TNF-α, IL-1β, and IL-6. Excessive activation can perpetuate epithelial damage and delay structural restoration. Balanced inflammatory modulation supports the transition from acute signaling toward resolution. Components within this formulation have been examined for their influence on:

• NF-κB pathway activity
• MAPK cascade modulation
• Cytokine expression patterns
• Epithelial–immune communication

Regulated inflammatory signaling allows epithelial repair processes to proceed without prolonged tissue destabilization.

Epithelial Restitution and Surface Continuity

Following injury, epithelial cells must migrate laterally to re-cover exposed areas. This process involves cytoskeletal reorganization, integrin signaling, and focal adhesion remodeling. Efficient restitution restores surface continuity before full structural regeneration occurs. Disruption of this process prolongs permeability defects. Peptides in this formulation have been studied for their influence on cytoskeletal dynamics and epithelial migration mechanisms. Supporting restitution dynamics enhances:

• Rapid surface resealing
• Reduced exposure to luminal stressors
• Improved structural resilience

Microvascular Support and Mucosal Oxygenation

Intestinal mucosa relies on an intact microvascular network for oxygen delivery and nutrient exchange. Inflammation can impair microcirculation and endothelial responsiveness. Support of angiogenic signaling and nitric oxide–related pathways contributes to mucosal stabilization. Improved microvascular balance supports:

• Oxygenation of epithelial cells
• Nutrient supply for regeneration
• Waste removal
• Barrier function recovery

Microvascular integrity is a structural component of intestinal repair, not merely a secondary factor.

Oxidative Stress Regulation

Inflamed mucosal environments often exhibit increased reactive oxygen species (ROS). Excess oxidative burden damages proteins, lipids, and cellular membranes, further compromising barrier integrity. Redox balance supports:

• Preservation of tight junction proteins
• Maintenance of epithelial cell viability
• Protection of microvascular endothelium

Components in this complex have been examined for interaction with redox-sensitive transcription systems and ROS modulation. Reducing oxidative amplification contributes to a more stable epithelial environment.

Integrated Barrier Function Restoration

Intestinal barrier dysfunction is multi-factorial. It involves structural disassembly, inflammatory amplification, oxidative stress, and microvascular instability occurring simultaneously. Addressing only one domain often leaves others unregulated. This formulation reflects the biological reality that barrier restoration requires coordination between:

• Tight junction stability
• Controlled inflammatory signaling
• Epithelial migration
• Microvascular support
• Redox balance

Rather than focusing on a single mechanism, the complex is structured to explore how these processes interact when addressed simultaneously.

Integrated Conclusion

Intestinal permeability and inflammatory dysregulation represent interconnected structural and signaling disturbances within the mucosal environment. Restoration of barrier integrity requires more than suppression of inflammation; it requires structural stabilization, controlled immune signaling, epithelial restitution, and vascular support working in concert. Intestinal Inflammation Permeability Complex is designed to support advanced research into these coordinated mechanisms governing mucosal resilience and epithelial structural regulation.

Individual Component Roles

• BPC-157 Arginate: The arginate salt form demonstrates enhanced physicochemical stability compared to acetate forms under simulated gastric conditions. At the molecular level, BPC-157 has been studied for its interaction with nitric oxide (NO)–related signaling pathways. Experimental data suggest that it may influence endothelial nitric oxide synthase (eNOS) activity and modulate NO-dependent vascular responses in preclinical systems. The nitric oxide pathway plays a central role in epithelial microcirculation, redox balance, and inflammatory signaling modulation within the intestinal microenvironment. In models of epithelial injury, BPC-157 has been associated with accelerated restitution processes. Experimental systems suggest that it may influence cytoskeletal reorganization, focal adhesion dynamics, and integrin-mediated signaling pathways that contribute to epithelial surface continuity. Investigative models have also explored its influence on angiogenic signaling cascades, including VEGF-associated pathways. Angiogenesis within damaged mucosal tissue supports nutrient delivery, oxygenation, and restoration of barrier function in controlled experimental environments. Preclinical findings suggest interaction with NF-κB signaling pathways and downstream cytokine expression patterns, including TNF-α, IL-1β, and IL-6. Experimental modulation of this pathway may influence epithelial–immune cross-talk under inflammatory microenvironment conditions. Models examining intestinal injury have also investigated potential influence on tight junction recovery. Tight junction proteins such as occludin and claudins are critical for maintaining selective permeability across epithelial layers.
• Larazotide Acetate: Larazotide acetate (AT-1001) is a synthetic octapeptide investigated as a regulator of epithelial tight junction dynamics. Its primary mechanistic focus in experimental research involves modulation of zonulin-associated signaling pathways. Zonulin is a physiological regulator of intercellular tight junctions. Under experimental inflammatory conditions, zonulin release can promote reversible disassembly of tight junction complexes, increasing paracellular permeability. Larazotide has been studied as an antagonist of zonulin-mediated signaling events. In epithelial cell culture systems, it has been observed to influence the structural organization of tight junction proteins, including occludin, claudins, and zonula occludens (ZO-1). Cytokines such as TNF-α and IL-4 are known in research settings to induce tight junction disassembly. Larazotide has been evaluated for its capacity to attenuate cytokine-induced permeability changes in vitro. Zonulin signaling interacts with epidermal growth factor receptor (EGFR) transactivation pathways and intracellular cascades involving protein kinase C (PKC) and actin cytoskeletal remodeling. Larazotide’s antagonistic activity appears to stabilize junctional complexes by limiting zonulin-triggered signaling amplification. In barrier dysfunction models, Larazotide has been examined for its effect on epithelial permeability markers and transepithelial electrical resistance (TEER) measurements, a quantitative method for evaluating tight junction integrity in vitro.
• KPV: KPV is the C-terminal peptide fragment of alpha-melanocyte-stimulating hormone (α-MSH). Composed of lysine, proline, and valine, it has been extensively studied in experimental and preclinical settings for its role in inflammatory signaling modulation. Research has explored KPV in gastrointestinal inflammatory models, where it has been associated with reduced inflammatory cell infiltration and modulation of inflammatory mediators such as TNF-α. Experimental data indicate that KPV can inhibit nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways, both central regulators of inflammatory cascades. Research led by Didier Merlin demonstrated that KPV may enter small intestinal epithelial cells via the PepT1 transporter, which is upregulated during inflammatory states. This mechanism may explain its increased activity in inflamed tissue models.

REFERENCES

All observations described above originate from in vitro systems, animal studies, or other preclinical experimental models and do not imply therapeutic, diagnostic, or preventive applications.

G. Dalmasso et al., "PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation" [Gastroenterology]

S.J. Getting et al., "Dissection of the Anti-Inflammatory Effect of the Core and C-Terminal (KPV) α-Melanocyte-Stimulating Hormone Peptides" [Journal of Pharmacology and Experimental Therapeutics]

S.C. Land "Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists" [PMC]

T.A. Luger et al., "α‐MSH related peptides: a new class of anti‐inflammatory and immunomodulating drugs" [PMC]

M. Bohm et al., "Are melanocortin peptides future therapeutics for cutaneous wound healing?"  [Wiley Online Library]

E. Viennois et al., "Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of the Anti-inflammatory PepT1-Mediated Tripeptide KPV in a Murine Model" [PMC]

S. Khaleghi et al., "The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate" [Sigma-Aldrich]

A. Duzel et al., "Stable gastric pentadecapeptide BPC 157 in colitis and ischemia models" [PMC]

P.S. Sikiric et al., "Effect of Pentadecapeptide BPC 157 on Gastrointestinal Tract" [Karger]

R. Klicek et al., "Pentadecapeptide BPC 157, in Clinical Trials as a Therapy for Inflammatory Bowel Disease (PL14736), Is Effective in the Healing of Colocutaneous Fistulas in Rats: Role of the Nitric Oxide-System" [ScienceDirect]

P. Sikiric et al., "Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157"  [Department of Pharmacology and Department of Pathology, Medical Faculty University of Zagreb, Croatia]

S. Seiwerth et al., "Stable Gastric Pentadecapeptide BPC 157 and Wound Healing" [Department of Pathology, School of Medicine, University of Zagreb]

J. Troisi et al., "The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases" [PubMed]

N.E. Castillo et al., "Celiac Disease as a Model Disorder for Testing Novel Autoimmune Therapeutics"  [ScienceDirect]

Z.M. Slifer et al., "Larazotide acetate: a pharmacological peptide approach to tight junction regulation" [American Journal of Physiology-Gastrointestinal and Liver Physiology]

C.P. Kelly et al., "Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study"  [AP&T]

B. Jancin "Larazotide eased symptoms in phase II celiac trial" [MDedge]

T. Vanuytsel et al., "The Role of Intestinal Permeability in Gastrointestinal Disorders and Current Methods of Evaluation"  [Frontiers]

DISCLAIMER

This product is intended for laboratory research and development use only. It is not a medicine or drug and has not been approved by the FDA, EMA, or any regulatory authority for the prevention, treatment, or cure of any disease.

Bodily introduction into humans or animals is strictly prohibited. Handling is restricted to qualified laboratory professionals.

All product information provided on this website is for informational and educational purposes only.